Vivos Therapeutics News

Vivos Therapeutics Price Target Maintained With a $6.60/Share by Ascendiant Capital

Dow JonesNov 20 17:54

Vivos Therapeutics Is Maintained at Buy by Alliance Global Partners

Dow JonesNov 20 01:09

Vivos Therapeutics Analyst Ratings

BenzingaNov 20 00:58

A. G. P. Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $6

Futu NewsNov 19 20:31

Vivos Therapeutics Analyst Ratings

BenzingaAug 20 17:34

Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.6

BenzingaAug 20 17:34

Ascendiant Remains a Buy on Vivos Therapeutics (VVOS)

TipRanksApr 12, 2023 15:10

Vivos Therapeutics Analyst Ratings

Benzinga Analyst RatingsJan 17, 2023 18:41